Director, Global Commercial Strategy Oncology – BioNTech/Solid Tumor at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

Advanced degree in business, life sciences, or related field (MBA, PhD, PharmD preferred)
Minimum 7 years of experience in oncology commercial strategy, marketing, or related roles within the pharmaceutical/biotech industry
Proven ability to lead cross-functional teams and influence stakeholders in a matrixed global environment
Deep understanding of the oncology market landscape, including solid tumors and immuno-oncology
Strong analytical, strategic planning, and communication skills
Experience with asset launches, lifecycle management, and business development is preferred
Strategic agility and commercial acumen
Cross-functional collaboration and stakeholder management
Results orientation and accountability
Change leadership and adaptability
Talent development and team leadership

Responsibilities

Lead the development and execution of global commercial strategies for BioNTech and solid tumor assets, in alignment with overall oncology portfolio objectives
Partner closely with Tumor Leads, Business Development, Medical, Market Access, and other stakeholders to drive integrated franchise plans and end-to-end accountability
Analyze market trends, competitive intelligence, and customer insights to inform strategic decisions and identify growth opportunities
Support launch readiness and lifecycle management for pipeline and in-market assets, including scenario planning and risk mitigation
Collaborate with Portfolio Strategy & Operations, Market Foresight, and Project Management teams to ensure operational excellence and cross-tumor alignment
Contribute to business development activities, including asset evaluation and partnership opportunities
Prepare and present business cases, strategic recommendations, and performance updates to senior leadership
Mentor and develop talent within the franchise, supporting succession planning and team capability building

Skills

Strategic Planning

Commercial Strategy

Oncology

Market Analysis

Competitive Intelligence

Cross-Functional Leadership

Franchise Management

Launch Readiness

Business Development

Market Access

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free